|
BRPI0607241A2
(pt)
*
|
2005-01-26 |
2009-08-25 |
Hoffmann La Roche |
derivados de fenil metanona e o uso dos mesmos como inibidores do transportador de glicina 1
|
|
CA2612585A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Amgen Inc. |
Anti-inflammatory aryl nitrile compounds
|
|
CN102775396B
(zh)
*
|
2005-11-08 |
2014-10-08 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的杂环调控剂
|
|
BRPI0709596A2
(pt)
*
|
2006-03-16 |
2011-07-19 |
Renovis Inc |
compostos bicicloeteroarila como moduladores de p2x7 e seus usos
|
|
WO2007109172A2
(en)
*
|
2006-03-16 |
2007-09-27 |
Renovis, Inc. |
Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
|
|
TWI464148B
(zh)
*
|
2006-03-16 |
2014-12-11 |
Evotec Us Inc |
作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
EP2674428B1
(en)
|
2006-04-07 |
2016-04-06 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US7754739B2
(en)
*
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
|
EA201300152A1
(ru)
*
|
2006-11-27 |
2013-07-30 |
Х. Лундбекк А/С |
Гетероариламидные производные
|
|
JP2010520875A
(ja)
*
|
2007-03-09 |
2010-06-17 |
レノビス， インコーポレイテッド |
Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用
|
|
BRPI0809567A2
(pt)
*
|
2007-04-10 |
2014-09-23 |
Lundbeck & Co As H |
Composto, composição farmacêutica, método para modular a atividade de um receptor de p2x7, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, e para determinar a presença ou ausência do receptor de p2x7 em uma amostra, preparação farmacêutica acondiciaonada, e, uso de um composto
|
|
JP5498374B2
(ja)
*
|
2007-04-17 |
2014-05-21 |
エボテック・アーゲー |
２−シアノフェニル縮合複素環式化合物および組成物、ならびにその使用
|
|
CN104447716A
(zh)
|
2007-05-09 |
2015-03-25 |
沃泰克斯药物股份有限公司 |
Cftr调节剂
|
|
WO2009019503A2
(en)
*
|
2007-08-03 |
2009-02-12 |
Astrazeneca Ab |
P2x7 antagonists for use in the treatment of mood disorders
|
|
MX365732B
(es)
|
2007-12-07 |
2019-06-12 |
Vertex Pharma |
Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
|
|
EP3683218B1
(en)
|
2007-12-07 |
2024-09-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
|
|
NZ720282A
(en)
|
2008-02-28 |
2017-12-22 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
|
CN102046240B
(zh)
|
2008-03-25 |
2014-06-25 |
阿费克蒂斯药品公司 |
新的p2x7r拮抗剂及其应用
|
|
CA2722035C
(en)
*
|
2008-04-22 |
2016-10-11 |
Janssen Pharmaceutica Nv |
Quinoline or isoquinoline substituted p2x7 antagonists
|
|
US8232273B2
(en)
*
|
2008-12-19 |
2012-07-31 |
Genentech, Inc. |
Heterocyclic compounds and methods of use
|
|
WO2010118921A1
(en)
|
2009-04-14 |
2010-10-21 |
Affectis Pharmaceuticals Ag |
Novel p2x7r antagonists and their use
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
MX2012011655A
(es)
|
2010-04-07 |
2012-11-23 |
Vertex Pharma |
Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
|
|
JP2013523833A
(ja)
|
2010-04-07 |
2013-06-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
|
|
MX353408B
(es)
|
2010-04-22 |
2018-01-11 |
Vertex Pharma |
Proceso para producir compuestos de cicloalquilcarboxamido-indol.
|
|
EP2569281A1
(en)
|
2010-05-14 |
2013-03-20 |
Affectis Pharmaceuticals AG |
Novel methods for the preparation of p2x7r antagonists
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
WO2012110190A1
(en)
|
2011-02-17 |
2012-08-23 |
Affectis Pharmaceuticals Ag |
Novel p2x7r antagonists and their use
|
|
WO2012163456A1
(en)
|
2011-05-27 |
2012-12-06 |
Affectis Pharmaceuticals Ag |
Novel p2x7r antagonists and their use
|
|
WO2012163792A1
(en)
|
2011-05-27 |
2012-12-06 |
Affectis Pharmaceuticals Ag |
Novel p2x7r antagonists and their use
|
|
CN103687860B
(zh)
|
2011-07-22 |
2016-06-08 |
埃科特莱茵药品有限公司 |
作为p2x7受体拮抗剂的杂环酰胺衍生物
|
|
TWI561521B
(en)
*
|
2011-10-14 |
2016-12-11 |
Abbvie Inc |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
WO2013070961A1
(en)
|
2011-11-08 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
EA024204B1
(ru)
|
2012-01-20 |
2016-08-31 |
Актелион Фармасьютиклз Лтд. |
Производные гетероциклических амидов в качестве антагонистов p2xрецептора
|
|
NZ727015A
(en)
|
2012-01-25 |
2017-12-22 |
Vertex Pharma |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
AR092857A1
(es)
|
2012-07-16 |
2015-05-06 |
Vertex Pharma |
Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
AR093921A1
(es)
|
2012-12-12 |
2015-06-24 |
Actelion Pharmaceuticals Ltd |
Derivados de indol carboxamida como antagonistas del receptor p2x7
|
|
KR102232744B1
(ko)
|
2012-12-18 |
2021-03-26 |
이도르시아 파마슈티컬스 리미티드 |
Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
ES2616883T3
(es)
|
2013-01-22 |
2017-06-14 |
Actelion Pharmaceuticals Ltd. |
Derivados amida heterocíclicos como antagonistas del receptor P2X7
|
|
KR102222220B1
(ko)
|
2013-01-22 |
2021-03-03 |
이도르시아 파마슈티컬스 리미티드 |
Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
|
|
TWI627174B
(zh)
|
2013-03-14 |
2018-06-21 |
比利時商健生藥品公司 |
Ｐ２ｘ７調控劑
|
|
WO2014152537A1
(en)
|
2013-03-14 |
2014-09-25 |
Janssen Pharmaceutica Nv |
P2x7 modulators
|
|
ES2654288T3
(es)
|
2013-03-14 |
2018-02-13 |
Janssen Pharmaceutica, N.V. |
Moduladores de P2X7
|
|
TWI644671B
(zh)
|
2013-03-14 |
2018-12-21 |
比利時商健生藥品公司 |
Ｐ２ｘ７調節劑
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
AU2014349010C1
(en)
|
2013-11-12 |
2020-08-06 |
Vertex Pharmaceuticals Incorporated |
Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
|
|
RU2744460C2
(ru)
|
2014-04-15 |
2021-03-09 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
|
|
WO2016039983A1
(en)
|
2014-09-12 |
2016-03-17 |
Janssen Pharmaceutica Nv |
P2x7 modulating n-acyl-triazolopyrazines
|
|
CA2960968A1
(en)
|
2014-09-12 |
2016-03-17 |
Janssen Pharmaceutica Nv |
P2x7 modulators
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
RU2691136C2
(ru)
|
2014-11-18 |
2019-06-11 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
WO2017003723A1
(en)
|
2015-07-01 |
2017-01-05 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
|
CN105198810B
(zh)
*
|
2015-07-16 |
2018-01-05 |
西安交通大学 |
2‑苄基‑1‑异喹啉酮类化合物及其合成方法和用途
|
|
CN105503724B
(zh)
*
|
2016-01-20 |
2018-01-30 |
湘潭大学 |
一种多取代2‑苄基‑1‑异喹啉酮类化合物的制备方法
|
|
EP3495363B1
(en)
|
2016-07-28 |
2023-08-23 |
Shionogi & Co., Ltd |
Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
US11028068B2
(en)
|
2017-07-25 |
2021-06-08 |
Crinetics Pharmaceuticals, Inc. |
Somatostatin modulators and uses thereof
|
|
MX2020003242A
(es)
|
2017-09-22 |
2020-09-18 |
Jubilant Epipad LLC |
Compuestos heterociclicos como inhibidores de pad.
|
|
AU2018352142B2
(en)
|
2017-10-18 |
2022-08-25 |
Jubilant Epipad LLC |
Imidazo-pyridine compounds as PAD inhibitors
|
|
KR20200085836A
(ko)
|
2017-11-06 |
2020-07-15 |
주빌런트 프로델 엘엘씨 |
Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
|
|
BR112020010322A2
(pt)
|
2017-11-24 |
2020-11-17 |
Jubilant Episcribe Llc |
composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
|
|
EP3744721B1
(en)
|
2018-01-26 |
2025-07-02 |
Shionogi & Co., Ltd. |
Condensed ring compounds having dopamine d3 receptor antagonistic effect
|
|
SG11202008950PA
(en)
|
2018-03-13 |
2020-10-29 |
Jubilant Prodel LLC |
Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
WO2020065614A1
(en)
|
2018-09-28 |
2020-04-02 |
Janssen Pharmaceutica Nv |
Monoacylglycerol lipase modulators
|
|
EP3856178B1
(en)
|
2018-09-28 |
2026-03-11 |
Janssen Pharmaceutica NV |
Monoacylglycerol lipase modulators
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
MX2022003819A
(es)
|
2019-09-30 |
2022-05-11 |
Janssen Pharmaceutica Nv |
Ligandos de pet de mgl radiomarcados.
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
BR112022019077A2
(pt)
|
2020-03-26 |
2022-12-27 |
Janssen Pharmaceutica Nv |
Moduladores da monoacilglicerol lipase
|
|
FI4143183T3
(fi)
|
2020-04-29 |
2026-01-07 |
Gasherbrum Bio Inc |
Heterosyklisiä glp-1-agonisteja
|
|
PE20231181A1
(es)
|
2020-08-06 |
2023-08-11 |
Gasherbrum Bio Inc |
Agonistas del glp-1 heterociclicos
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2023179542A1
(en)
*
|
2022-03-21 |
2023-09-28 |
Gasherbrum Bio , Inc. |
5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
|
|
CN118908892B
(zh)
*
|
2024-07-18 |
2025-10-31 |
武汉大学 |
氨基异喹啉类衍生物及其在制备抗病毒药物中的应用
|